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Background
Tat, the HIV Trans-Activator of Transcription is a
potential antiviral target. Tat binds to the 5’ terminal
region of HIV mRNAs stem-bulge-loop structure called
the Trans-activation Responsive (TAR) element and
activates transcription from the HIV promoter. Plasma
viremia stubbornly persists in HIV-1 infected subjects
despite receiving HAART, suggesting that residual levels
of viral production originate from an integrated form of
the HIV genome that is continuously transcribed at low
levels. As current antiretrovirals (ARVs) fail to inhibit
transcription from integrated viral genomes or viral pro-
duction from stable cellular reservoirs, novel classes of
ARVs are needed to inhibit this process.
Results
Cortistatin A is a steroidal alkaloid isolated from the
marine sponge Corticium simplex. Here, we show that its
analog didehydro-Cortistatin A (dCA) inhibits Tat-
mediated trans-activation of the integrated HIV provirus
by binding specifically to the TAR-binding domain of
Tat. dCA reduces cell-associated viral RNA and capsid
p24 antigen production in acutely and chronically
infected cultured and primary cells, at a half maximal
effective concentration (EC50)o f0 . 7p Mt o2 . 5n M ,
depending on the multiplicity of infection (MOI). dCA
reduces both transcriptional initiation/elongation from
the viral promoter and alters the nucleolar localization of
Tat. Termination of dCA treatment does not result in
immediate virus rebound as the HIV promoter is tran-
scriptionally silenced. dCA inhibits both HIV-1 and HIV-
2, and displays high bioavailability. dCA added to a
combination of ARVs mediates a statistically significant
reduction in viral replication from primary CD4
+T cells
isolated from viremic patients compared to the ARVs
alone, and abrogates low-level virus replication from
CD4
+T cells isolated from aviremic patients undergoing
HAART treatment.
Conclusions
With a therapeutic index of over 8000, dCA defines a
novel class of HIV anti-viral drugs endowed with the
ability to decrease residual viremia during HAART, and
should be considered as a promising drug to be included
in therapeutic eradication strategies.
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